A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT04123795. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.
Study identification
- NCT ID
- NCT04123795
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 49 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 20, 2020
- Primary completion
- Apr 8, 2026
- Completion
- Jul 22, 2026
- Last update posted
- Aug 3, 2026
2020 – 2026
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ps0007 50175 | Phoenix | Arizona | 85006 | — |
| Ps0007 50162 | Fountain Valley | California | 92708 | — |
| Ps0007 50161 | Los Angeles | California | 90045 | — |
| Ps0007 50196 | Thousand Oaks | California | 91320 | — |
| Ps0007 50217 | Boca Raton | Florida | 33428 | — |
| Ps0007 50248 | Hialeah | Florida | 33016 | — |
| Ps0007 50169 | Jacksonville | Florida | 32256 | — |
| Ps0007 50268 | Miami | Florida | 33155 | — |
| Ps0007 50269 | Wellington | Florida | 33449 | — |
| Ps0007 50230 | Rome | Georgia | 30161 | — |
| Ps0007 50168 | Chicago | Illinois | 60611 | — |
| Ps0007 50286 | Topeka | Kansas | 66614 | — |
| Ps0007 50232 | Detroit | Michigan | 48202 | — |
| Ps0007 50156 | Arlington | Texas | 76011 | — |
| Ps0007 50277 | San Antonio | Texas | 78218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04123795, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04123795 live on ClinicalTrials.gov.